Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database

This real-world study identifies drugs potentially linked to MGD, offering valuable insights for drug safety surveillance. These findings support the development of pharmacovigilance strategies and optimized clinical practice to mitigate ocular risks.